Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab With or Without Thalidomide in Relapsed/Refractory Multiple Myeloma
NCT00022607Phase 2Completed
- Sponsor
- California Cancer Consortium
- Start
- Jan 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in multiple myeloma (MM), sponsored by California Cancer Consortium. Started Jan 2002; status: completed.
02
Drugs
bevacizumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00022607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022607.